Susan Pitman, MD
Obstetrics & Gynecology · West Orange, NJNPI 1548378003
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $72,800 of the $76,506 with a category attached, or 95.2%. Celularity Inc. accounts for 99.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $73,136 and has fallen 99.9% since, to $49 in 2025. Among obstetrics & gynecology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 19 payments — averaging $4026.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Celularity Inc.$76K
- Johnson & Johnson$49
- Exeltis, USA Inc.$36
- Bayer$21
What the payments were for
- Consulting fees$72,80095%
- Speaking & faculty fees$3,6005%
- Food & beverage$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Celularity Inc. | 14 | $76,400 |
| Johnson & Johnson | 1 | $49 |
| Exeltis, USA Inc. | 3 | $36 |
| Bayer | 1 | $21 |
How this compares
$76,506 in reported general payments places this provider in the 95th percentile of 1,242 obstetrics & gynecology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 30 | $20,886 |
| EstringEstradiol | 27 | $14,456 |
| Estradiol | 109 | $7,727 |
| PremproEstrogen,con/M-Progest Acet | 14 | $7,376 |
| Raloxifene Hcl | 39 | $1,973 |
| ValacyclovirValacyclovir Hcl | 35 | $1,877 |
| Ibandronate Sodium | 37 | $1,542 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 28 | $537 |
| Metronidazole | 13 | $512 |
| Acyclovir | 11 | $386 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 31 | $380 |
| Fluconazole | 17 | $197 |
| Alprazolam | 20 | $126 |
| Alendronate Sodium | 19 | $93 |
| Triamcinolone Acetonide | 12 | $69 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in West Orange
- Robert RubinoWest Orange$42K
- Jacqueline SaittaWest Orange$9K
- Jennifer AshtonEnglewood$1.5M
- Geoffrey BowersVoorhees$228K
- Neha DeshpandePlainsboro$206K
- Paula JasionowskiVoorhees$193K
- Justin ChuraSwedesboro$179K
- Andrea VentolaFlorham Park$145K
- Aiman ShiladPaterson$100K
- Patrick CulliganMorristown$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.